Nick's lab studies how cells regulate their behavior, a field sometimes termed cell signalling, and how this regulation fails in cancer. In particular Nick and his group have investigated the tumour suppressor protein PTEN and why the loss of PTEN function is a common step in the development of many cancers.
Berglund, FM, Weerasinghe, NR, Davidson, L, Lim, JC, Eickholt, BJ and Leslie NR (2013). Disruption of epithelial architecture caused by loss of PTEN or by oncogenic mutant p110/PIK3CA but not by HER2 or mutant AKT1. Oncogene 32, 4417-26
Tibarewal P, Zilidis G, Spinelli L, Schurch N, Maccario H, Gray A, Perera NM, Davidson L, Barton GJ, and Leslie NR (2012). PTEN protein phosphatase activity correlates with control of invasion, gene expression and tumour suppression, but not AKT. Science Signaling, 5, ra18.
Leslie NR and Foti M (2011). Non-genomic loss of PTEN in cancer: not in my genes. Trends in Pharmacological Sciences. 32, 131-40
Maccario H, Perera NM, Gray A, Downes CP and Leslie NR (2010). Ubiquitination of PTEN inhibits phosphatase activity and is enhanced by membrane targeting and hyperosmotic stress. J. Biol. Chem. 285, 12620-8
Leslie NR, Yang X, Downes CP and Weijer CJ (2007). PtdIns(3,4,5)P3-dependent and –independent roles for PTEN in the control of cell migration. Current Biol. 17, 115-125
Nick studied for a first degree in Genetics at Cambridge University and a PhD at Glasgow University with David Sherratt. After PostDoctoral research with Paul Harrison at the Beatson Institute for Cancer Research in Glasgow, he moved to Dundee to work with Peter Downes and Philip Cohen at the inception of their pharmaceutical collaboration, the Division of Signal Transduction Therapy. He was appointed as an Independent Investigator in 2002 and as an RCUK Academic Fellow in 2006. In January 2013, Nick moved to the new Institute of Biological Chemistry, Biophysics and Bioengeneering at Heriot Watt University as a Reader.